New shot aims to cure chronic hepatitis b – early trial underway
NCT ID NCT06550128
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new drug called AHB-137 in 86 adults with chronic hepatitis B who are already on standard antiviral pills. The goal is to see if AHB-137 can clear the hepatitis B surface antigen from the blood, which would mean the virus is under control and patients might be able to stop their daily medication. Participants receive injections of AHB-137 or a placebo over several weeks, and researchers monitor safety and effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AHB-137 injection
What this could lead to
If successful, this could point toward a functional cure for chronic hepatitis B, allowing patients to stop long-term antiviral medication.
What could go wrong
This is an early Phase 2 trial with only 86 participants. The drug may not achieve sustained viral clearance, and side effects are still being evaluated.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Friendship Hospital, Capital Medical University
Beijing, China
-
Mengchao Hepatobiliary Hospital of Fujian Medical University
Fuzhou, Fujian, China
-
Nanfang Hospital, Southern Medical University
Guangzhou, China
-
The First Hospital of Jilin University
Jilin City, China
-
The Second Affiliated Hospital of Chongqing Medical University
Chongqing, China
-
The third People's Hospital of Zhenjiang
Zhenjiang, Jiangsu, China